Celcuity "announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American Association for Cancer Research, or AACR, which will be held April 14-19, 2023 in Orlando, Florida. The abstract and poster presentation describe the potency and efficacy of gedatolisib and other PI3K/AKT/mTOR inhibitors using cell viability, cell proliferation, and flow cytometry assays in endometrial, ovarian, and cervical cancer cell lines."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CELC:
